DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1046756
Title:
A Novel Therapy for Inflammatory Bowel Disease-Dual Regulatory T-Cell Programming
Corporate Author:
Loma Linda University Loma Linda United States
Report Date:
2017-08-01
Abstract:
Inflammatory bowel disease IBD is a group of diseases that are conditions of chronic inflammation in the gastrointestinal tractthe GUT. Current therapies for IBD have a transient effect and are associated with significant side effects due to unintended immune suppression. Hence, a therapy that can lead to a more specific and lasting control of the gut inflammation is urgently needed. This study investigates a novel therapy that aims to induce gut-homing regulatory T Treg cells in the peripheral lymphoid tissues. We propose that the newly generated Treg cells can specifically home to and reinstate immune tolerance in the gut, thereby providing a long-lasting control of the chronic inflammation in the gut of IBD patients. This novel therapy is a dendritic cell DC that is engineered to de novo synthesize high concentrations of both the active vitamin D metabolite1,25OH2D and retinoid acid RA. We hypothesize that such engineered DC can home to and interact with T cells in the peripheral lymphoid tissues where the DC-derived and de novo synthesized focally high concentrations of 1,25OH2D and RA can promote the induction of regulatory and gut-homing molecules respectively in the same T cell that subsequently differentiates into a gut-homing Treg cell. We will test this hypothesis using an IBD animal model, i.e. experimental colitis.
Descriptive Note:
Technical Report,01 Aug 2016,31 Jul 2017
Pages:
0026
Distribution Statement:
Approved For Public Release;
File Size:
2.44MB
